Figure 6.

Exosome-activated HSCs enhance the lactate metabolism by activating the IL-6/STAT3 pathway in tumor cells. (A) Western blot analysis of the expression level of p-STAT3 and STAT3 in LoVo and HCT116 cells at 48 h after co-culture with HSCs medium or aHSCs medium with CoCl₂ and SN38. (B) Western blot analysis of the expression level of p-STAT3 and STAT3 in LoVo and HCT116 cells at 48 h after co-culture with the HSCs medium or aHSCs medium and CoCl₂, SN38 and IL-6 neutralizing antibodies. (C) Western blot analysis of the expression level of p-STAT3 and STAT3 in LoVo and HCT116 cells at 48 h after co-culture with the HSCs medium or aHSCs medium and CoCl₂, SN38 and Stattic. (D) Cell viability assays with LoVo and HCT116 cells after 48 h of the indicated treatment. (E) Flow cytometric analysis of the apoptosis of LoVo and HCT116 cells after 48 h of the indicated treatment. (F) Western blot analysis of the expression level of Bcl-2 and Bax in LoVo and HCT116 cells after 48 h of the indicated treatment. (G) Western blot analysis of the expression level of MCT1 and LDHB in LoVo and HCT116 cells after 48 h of the indicated treatment. (H) The relative production of ATP by LoVo and HCT116 after 48 h of the indicated treatment. N=3; ns, no significant difference; *P<0.05; **P<0.001.